Skip to main content

The Immune System

Under Control

Our Company

AbolerIS Pharma is a Belgian biopharmaceutical company developing a novel approach to the treatment of chronic autoimmune and inflammatory diseases.

Lead Program

AbolerIS Pharma is developing a first-in-class monoclonal antibody based on a novel scientific approach to restore the balance in the immune system.
Our novel and unique therapeutic approaches induce immune tolerance and preserve useful immune responses in inflammatory, autoimmune, and degenerative diseases.

Latest updates

AbolerIS Pharma is one of the laureates of the REACT-EU program 2022

| News, sticky | No Comments
Nantes, France, November 22, 2022 – AbolerIS Pharma is a pre-clinical stage biotech company specialized in the development of innovative immunomodulators for the treatment of transplant rejection, graft-versus-host-disease and auto-immune…

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

| News | No Comments
-Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- - ABO21009’s unique mechanism of action depletes pathogenic T and B cells,…

AbolerIS Pharma Announces Formation of Scientific Advisory Board

| News | No Comments
GOSSELIES, Belgium and NANTES, France, April 24, 2025 -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of…